<DOC>
	<DOCNO>NCT00001941</DOCNO>
	<brief_summary>The purpose study determine : ( 1 ) toxicity maximum tolerate dose ( MTD ) humanize anti-Tac ( daclizumab ) , ( Zenapax ( Registered Trademark ) ) patient adult T-cell leukemia/lymphoma ( ATL ) ; ( 2 ) define dose Zenapax ( Registered Trademark ) require saturate interleukin 2 receptor alpha ( IL-2R ) alpha patient ATL ; ( 3 ) determine clinical response humanize ( Hu ) anti-Tac ( Zenapax ( Registered Trademark ) patient Tac-expressing adult T-cell leukemia ; ( 4 ) determine serum dieaway curve ( pharmacokinetics ) infuse humanize ( Hu ) -anti-Tac patient ATL . This study represent extension Metabolism Branch National Cancer Institute ( NCI ) protocols utilizing modification original murine anti-Tac monoclonal antibody ( mAb ) develop group treatment ATL . The scientific basis therapeutic study leukemic cell patient ATL express abnormally high level Tac antigen ( IL-2R alpha ) surface whereas rest normal cell include normal T-cells patient . One presumed mode action Hu-anti-Tac treatment ATL involve interruption interaction interleukin 2 ( IL-2 ) growth factor receptor . To effective goal must maintain saturation IL-2 receptor ( IL-2R ) humanize anti-Tac thereby prevent IL-2 mediated proliferation yield cytokine deprivation apoptotic cell death leukemic cell . Eligible patient ATL treat escalate dos Zenapax ( Registered Trademark ) group Clinical Center National Institutes Health ( NIH ) . Groups patient receive sufficient Zenapax ( Registered Trademark ) yield saturation IL-2 receptor period 17 week . Clinical response evaluate use routine immunological clinical evaluation monitor saturation IL-2R absolute number residual circulating malignant cell fluorescence activate cell sorting ( FACS ) analysis use two fluorochrome-labeled non-crossreacting antibody IL-2 receptor , anti-Tac 7G7/B6 , well antibody cluster differentiation 3 ( CD3 ) , cluster differentiation 4 ( CD4 ) , cluster differentiation 7 ( CD7 ) , cluster differentiation 8 ( CD8 ) . Furthermore , response evaluate patient leukemia Southern blot analysis arrangement T-cell receptor gene human T-lymphotropic virus type 1 ( HTLV-I ) integration . Finally , select patient , define pharmacokinetics therapeutic antibody , plan monitor serum level infuse Hu-anti-Tac ( Zenapax ( Registered Trademark ) ) function time . This study essential element program involve IL-2R-directed therapeutic study . If anticipated therapy humanize anti-Tac yield partial complete remission patient ATL , propose use single agent patient smolder chronic ATL association chemotherapeutic agent provide novel approach treatment acute lymphoma form ATL . We also plan future clinical trial tentative plan also make evaluate efficacy toxicity ATL patient saturate dos Zenapax ( Registered Trademark ) compare identical dos Zenapax ( Registered Trademark ) give association ( 90 ) Y-armed 7G7/B6 , non-competing antibody IL-2R alpha combination chemotherapy .</brief_summary>
	<brief_title>Anti-Tac Treatment Leukemia</brief_title>
	<detailed_description>Background : Human T-lymphotropic virus type 1 ( HTLV-1 ) -associated adult T cell leukemia/lymphoma ( ATL ) aggressive lymphoproliferative disorder . Chemotherapy limited impact survival . The interleukin 2 receptor alpha ( IL-2R alpha ) ( CD25 ) express ATL cell smolder chronic stage ATL often interleukin 2 ( IL-2 ) dependent . The monoclonal antibody daclizumab ( Zenapax ) inhibit interleukin 2 ( IL-2 ) bind receptor . It hypothesize daclizumab may inhibit ATL growth . Objectives : To determine toxicity maximum tolerate dose ( MTD ) humanize anti-Tac ( daclizumab , Zenapax ) patient ATL . To define dose Zenapax require saturate IL-2R alpha patient ATL . To determine clinical response humanize ( Hu ) anti-Tac ( Zenapax ) patient Tac-expressing smolder chronic stage adult T cell leukemia . To determine serum dieaway curve ( pharmacokinetics ) infuse humanize ( Hu ) - anti - Tac patient ATL . Eligibility : Smoldering chronic stage HTLV-1-associated adult T cell leukemia . At least 5 percent malignant cell peripheral blood lymph node must react anti-Tac ( CD25 ) antibody . Age great equal 10-years-old . Patients must measurable disease . Patients without prior treatment . Patients must granulocyte count great equal 500/micro L , platelets great equal 25,000/micro L , creatinine le 3.0 gm/dL . Design : Phase I patient cohorts 1-4 receive following : cohort 1 : 2 mg/kg 60 minute intravenously day 1 2 ; cohort 2 : 4 mg/kg 90 minute intravenously day 1 , single dose ; cohort 3 : 6 mg/kg 90 minute intravenously day 1 , single dose ; cohort 4 : 8 mg/kg 90 minute intravenously day 1 , single dose . Patients smolder chronic stage ATL treat intravenous daclizumab 8 mg/kg day 0 week 2 , 5 , 8 , 11 14 . Patients achieve response continue treatment daclizumab 8 mg/kg every 3 week 24 month . Patients achieve complete response ( CR ) continue treatment daclizumab 8mg/kg every 3 week 24 month . Patients achieve partial response ( PR ) maintain daclizumab 8 mg/kg administer every 3 week provide PR maintain serious adverse event toxicity relate daclizumab therapy observe .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , T-Cell</mesh_term>
	<mesh_term>Leukemia-Lymphoma , Adult T-Cell</mesh_term>
	<mesh_term>HTLV-I Infections</mesh_term>
	<mesh_term>Daclizumab</mesh_term>
	<mesh_term>Immunoglobulin G</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<criteria>ELIGIBILITY CRITERIA : Population Base . Patients diagnose smolder chronic human Tlymphotropic virus type 1 ( HTLVI ) associate adult Tcell leukemia . INCLUSION CRITERIA : Patients must serum antibody direct HTLVI . All patient must histologically confirm diagnosis adult Tcell leukemia/lymphoma . At least 5 percent patient 's peripheral blood , lymph node , pulmonary dermal malignant cell must react antiTac mAb determine immunofluorescent staining , alternatively , serumsoluble interleukin 2 ( IL2 ) receptor level must great 1,000 units/ml ( normal geometric mean , 235 ; 95 % confidence interval 112 502 units/mL ) . Smoldering chronic stage Tacexpressing adult Tcell leukemia define Shimomyama Criteria ( 37 ) eligible . To diagnosed smolder Adult Tcell Leukemia ( ATL ) , patient must normal lymphocyte count ( less 4 time 10^3/mm^3 ) , less equal 5 percent abnormal lymphocytes morphologic examination peripheral blood smear fluorescence activate cell sorting ( FACS ) analysis ( cell homogenous stain pattern great 1 log increase magnitude fluorescence emission antiTac peak background expression ) , hypercalcemia , lactate dehydrogenase less equal 1.5 time upper limit normal , lymphadenopathy , involvement extra nodal organ except skin lung malignant pleural effusion ascites . If abnormal lymphocyte count le 5 percent , patient must least one histologically proven skin ATL lesion diagnose smolder ATL . Patients &gt; 5 % circulate lymphocyte abnormal consider measurable disease . The patient must granulocyte count least 500/mm^3 platelet count 25,000/mm^3 . Patients must creatinine less 3.0 mg/dl . Patients must Karnofsky performance score great 60 percent . ATL patient without , well , previous chemotherapy eligible inclusion study . Patients previous therapy monoclonal antibody include antiTac eligible study provide positive HAHA ( human antibody humanize antiTac ) value ( i.e. , patient must value great 250 ng/ml ) . Omission cytotoxic chemotherapy ATL 3 week prior entry trial require . However , patient receive corticosteroid exclude . Patients must life expectancy great 2 month . Eligible patient must great equal 10 year old . There upper age limit . Patients age 18 year must able understand sign Informed Consent form . Eligible minor great equal 10 year old must give assent participate study . EXCLUSION CRITERIA : Patients symptomatic central nervous system disease due adult Tcell leukemia exclude . However , patient ATL another HTLVIassociated disease , tropical spastic paraparesis ( TSP ) , include . Furthermore , Tacexpressing T cell may present cerebrospinal fluid ( CSF ) long patient symptomatic central nervous system ( CNS ) disease . Pregnant and/or nursing patient eligible study . Human immunodeficiency virus ( HIV ) positive patient exclude study . Patients serum glutamic oxaloacetic transaminase ( SGOT ) serum glutamic pyruvic transaminase ( SGPT ) value 5.0fold great upper limit normal bilirubin great 2.9 mg/dl exclude . If liver function test judged elevate due underlie ATL , parameter consider unevaluable parameter toxicity determination . Acute Lymphoma stage HTLV1 associate adult T cell leukemia .</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Interleukin-2 Receptor alpha chain</keyword>
	<keyword>Interleukin-2</keyword>
	<keyword>HTLV-I</keyword>
	<keyword>Adult T-Cell Leukemia ( ATL )</keyword>
	<keyword>Monoclonal Antibody ( Daclizumab , Zenapax )</keyword>
</DOC>